Skip to main content
SpringerLink
Log in

The pharmacokinetics of azapropazone

  • Chapter
Azapropazone

  • 54 Accesses

Abstract

The subject of pharmacology can conveniently be divided into two subsections, namely pharmacodynamics and pharmacokinetics. While pharmacodynamics deals with the therapeutic effects (both desirable and undesirable), i.e. what the drug does to the organism, pharmacokinetics deals with the kinetics of the processes of absorption, distribution and elimination of the drug, i.e. how the organism treats the drug. A careful study of the pharmacokinetic profile of a drug is desirable since the magnitude of both the desired therapeutic response and toxicity are often closely related to the concentration of the drug at its site(s) of action. This latter concentration can often be correlated with serum concentrations of the drug and it is via careful evaluation of serum drug concentrations, post administration, that the preliminary pharmacokinetic profile of a drug can be established.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 16.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Walker, FS (1985). Azapropazone and related benzotriazones. In: Rainsford, KD, (ed) Anti-inflamatory and Anti-rheumatic Drugs, Vol. II, Newer Anti-inflamatory Drugs. (Boca Raton: CRC Press) pp. 1–32

    Google Scholar 

  2. Mixich, G (1968). Zum chemischen Verhalten des Antiphogistikums Azapropazon (Mi85) = 3-Dimethylamino-7-methyl-1,2-(n-propylmalonyl)-1,2-dihydro-1.2.4-benzotriazin. Helv. Chim. Acta, 51, 532

    Article  CAS  Google Scholar 

  3. Fenner, H and Mixich, G (1973) NMR-Untersuchungen zur Molekülstruktur von Azapropazon und Deutung seiner Pharmakokinetic und Biotransformation. Azneim. Forsch., 23, 667

    CAS  Google Scholar 

  4. Albengres, E, Urien, S, Riant, P, Marcel, GA and Tillement, JP (1987). Binding of two anthranilic acid derivatives to human albumin, erythrocytes and lipoproteins: evidence for glafenic acid high affinity binding. Mol. Pharmacol, 31, 294–300

    PubMed  CAS  Google Scholar 

  5. Klatt, VL and Koss, FW (1973). Pharmkokinetische Untersuchungen mit 14C-Azapropazon-Dihydrat an der Ratte. Arzneim. Forsch., 23, 913

    CAS  Google Scholar 

  6. Jahn, V, Relier, J and Schatz, F (1973). Pharmakokinetische Untersuchungen mit Azapropazon bei Tieren. Arzneim. Forsch., 23, 660–666

    CAS  Google Scholar 

  7. Jones, CJ (1976). The pharmacology and pharmacokinetics of azapropazone — a review. Curr. Med. Res. Opin., 4, 3–16

    Article  PubMed  CAS  Google Scholar 

  8. Sturman, JA and Smith, MJH (1967). The binding of salicylate to plasma proteins in different species. J. Pharm. Pharmacol., 19, 621–623

    Article  PubMed  CAS  Google Scholar 

  9. Schatz, F, Adrian, RW, Mixich, G, Molnarova, M, Relier, J and Jahn, U (1970). Pharmakokinetische Untersuchungen mid dem Antiphlogistikum Azapropazon (Prolixan 300) am Menschen. Therapiewoche, 20, 39

    Google Scholar 

  10. Klatt, VL and Koss, FW (1973). Human pharmakokinetische Untersuchungen mit 14C-Azapropazon-Dihydrat. Arzneim. Forsch., 23, 920–921

    CAS  Google Scholar 

  11. Evans, EF (1974). Data on file, AH Robins Co.

    Google Scholar 

  12. Leach, H (1976). The determination of azapropazone in blood plasma. Curr. Med. Res. Opin., 4, 35

    Article  PubMed  CAS  Google Scholar 

  13. Breuing, K-H, Gilfrich, H-J, Meinertz, T, Weigand, V-W and Jähnchen, E (1981). Disposition of Azapropazone in chronic renal and hepatic failure. Eur. J. Clin. Pharmacol, 20, 147–155

    Article  PubMed  CAS  Google Scholar 

  14. Rainsford, KD (1985). Distribution of azapropazone and its principal 8-hydroxy metabolite in plasma, urine and the gastrointestinal mucosa determined by HPLC. J. Pharm. Pharmacol, 37, 341–345.

    Article  PubMed  CAS  Google Scholar 

  15. Kline, BJ, Wood, JH and Beightol, LA (1983). The determination of azapropazone and its 6-hydroxy metabolite in plasma and urine by HPLC. Arzneim. Forsche., 33, 504–506

    CAS  Google Scholar 

  16. Jähnchen, E, Blanck, KJ, Breuing, K-H, Gilfrich, H-J, Meinertz, T and Trenk, D (1981). Plasma protein binding of azapropazone in patients with kidney and liver disease. Br. J. Clin. Pharmacol, 11, 361–367

    PubMed  Google Scholar 

  17. Urien, S, Albengres, E, Pinquier, JL and Tillement, JP (1986). Role of alpha-1 acid glycoprotein, albumin and non-esterified fatty acids in serum binding of apazone and warfarin. Clin. Pharmacol. Ther., 39, 683–689

    Article  PubMed  CAS  Google Scholar 

  18. Ritch, AES, Perera, WNR and Jones, CJ (1982). Pharmakokinetics of azapropazone in the elderly. Br. J. Clin. Pharmacol, 14, 116–119

    PubMed  CAS  Google Scholar 

  19. Aylward, M, Baker, PA, Davies, DE, Hutchings, L, Lewis, PA, Maddock, J and Protheroe, DA (1977). Data on file, AH Robins Co. (Simbec Research Laboratories, Merthyr Tydfil, Wales, UK)

    Google Scholar 

  20. Spahn, H, Thabe, K, Mutschler, E, Tillmann, K and Gikalov, I (1987). Concentration of azapropazone in synovial tissues and fluid. Eur. J. Clin. Pharmacol, 32, 303–307

    Article  PubMed  CAS  Google Scholar 

  21. Powell-Jackson, PR (1977). Interaction between azapropazone and warfarin. Br. Med. J., 1, 1193–1194

    Article  PubMed  CAS  Google Scholar 

  22. McElnay, JC and D’Arcy, PF (1980). Displacement of albumin-bound warfarin by anti-inflammatory agents in vitro. J. Pharm. Pharmacol, 32, 709–711

    Article  PubMed  CAS  Google Scholar 

  23. Diana, FJ, Veronich, K and Kapoor, AL (1989). Binding of nonsteroidal antiinflammatory agents and their effect on binding of racemic warfarin and its enantiomers to human serum albumin. J. Pharm. Sci., 78, 195–199

    Article  PubMed  CAS  Google Scholar 

  24. Lewis, RJ, Trager, WF, Chan, KK, Breckenridge, A, Orme, M, Roland, M and Schary, W (1974). Warfarin; stereochemical aspects of its metabolism and the interaction with phenylbutzone. J. Clin. Invest., 53, 1607–1617

    Article  PubMed  CAS  Google Scholar 

  25. Roberts, CJC, Daneschmend, TK, Macfarlane, D and Dieppe, PA (1981). Anticonvulsant intoxication precipitated by azapropazone. Postgrad. Med. J., 57, 191–192

    Article  PubMed  CAS  Google Scholar 

  26. Geaney, DP, Carver, JG, Davis, CL and Aronson, JK (183). Pharmacokinetic investigation of the interaction of azapropazone with phenytoin. Br. J. Clin. Pharmcol., 15, 727–734

    Google Scholar 

  27. Andreasen, PB, Simonsen, K, Brocks, K, Dimo, B and Bouchelouche, P (1981). Hypoglycaemia induced by azapropazone-tölbutamide interaction. Br. J. Clin. Pharmacol, 12, 581–583

    PubMed  CAS  Google Scholar 

  28. Waller, DG and Waller, D (1984). Hypoglycaemia due to azapropazone-tolbutamide interaction. Br. J. Rheumatol, 23, 24–25

    Article  PubMed  CAS  Google Scholar 

  29. Daly, H, Boyle, J, Roberts, C and Scott, G (1986). Interaction between methotrexate and non-steroidal anti-inflammatory drugs. Lancet, 1, 557.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. J. C. McElnay
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. F. S. Walker
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Biomedical Sciences, McMaster University Faculty of Health Sciences, 1200 Main St W, Hamilton, Ontario, L8N 3Z5, Canada

    K. D. Rainsford

Rights and permissions

Reprints and permissions

Copyright information

© 1989 Kluwer Academic Publishers

About this chapter

Cite this chapter

McElnay, J.C., Walker, F.S. (1989). The pharmacokinetics of azapropazone. In: Rainsford, K.D. (eds) Azapropazone. Springer, Dordrecht. https://doi.org/10.1007/978-94-009-0713-3_6

Download citation

  • DOI: https://doi.org/10.1007/978-94-009-0713-3_6

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-94-010-6806-2

  • Online ISBN: 978-94-009-0713-3

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation